Related Experiment Videos
Institutional pharmacists' guide to complying with PPI regulations
American Journal of Hospital Pharmacy
|December 1, 1980
Summary
The Food and Drug Administration (FDA) now requires patient package inserts (PPIs) for 10 specific drugs and drug classes. This regulation impacts institutional pharmacists, with a three-year trial period for evaluation.
Area of Science:
- Pharmaceutical Policy
- Drug Regulation
- Health Communication
Background:
- The Food and Drug Administration (FDA) issued a significant omnibus regulation mandating patient package inserts (PPIs).
- This regulation targets specific high-risk drugs and drug classes, necessitating changes in dispensing practices.
Purpose of the Study:
- To discuss the implications of the new FDA regulation on patient package inserts (PPIs) for institutional pharmacists.
- To outline the scope of the regulation, including the drugs and drug classes involved and the trial period.
Main Methods:
- Review of the FDA's final rule on mandatory patient package inserts (PPIs).
- Identification of the 10 specific drugs and drug classes subject to the regulation.
- Discussion of institutional options for PPI dissemination to inpatients.
Main Results:
- A three-year trial period is established for the PPI mandate, commencing September 12, 1980.
- The regulation includes specific drugs (e.g., warfarin, digoxin) and drug classes (e.g., benzodiazepines).
- The FDA will conduct a cost-benefit analysis during the trial period.
Conclusions:
- Institutional pharmacists must adapt to the new PPI dispensing requirements.
- Alternative systems for providing PPIs to inpatients are permissible.
- Recommendations for implementing the PPI program within healthcare institutions are provided.